The system
How the system worksThe DirectoryDispatchThe LedgerAI modelsAI agentsYour installationThe appThe research libraryWhat changes for your businessUse it from your softwareEverything it can do
Messaging
iMessageWhatsApp
Ads and leads
AdsCreativeLeads
Devices
Devices
Industries
RealtorsRestaurantsHome services
Explore
How it worksPermissions and limitsCompareSet upQuestionsText me

Selank × GLP-1 agonists (class)

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits. Studied for anxiolytic pathways without classic

Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: glp1 agonists. Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

Logic chain

  1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
  2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
  3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
  4. This chain is tested in animal or lab models only.

Parent peptide claims relevant here

  • In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
  • Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
  • Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
  • 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
  • 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

What we do not know

  • Whether selank reaches glp1 agonists tissue at functional concentrations
  • Optimal dosing, route, and duration for this target
  • Interaction with standard-of-care treatments for glp1 agonists
  • Long-term safety profile in this population

Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.